Clinical Trial Update: AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone [Phase 2]

View source ↗

Summary

Phase 2 trial of plerixafor (AMD3100) in multiple myeloma or non-Hodgkin lymphoma patients predicted to be unable to mobilize with G-CSF alone was terminated, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Non-hodgkin Lymphoma

Drugs mentioned

• Plerixafor (Plerixafor)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's | Phase 2 | Status: TERMINATED | Results posted: 2010-08-13